Free Trial
NASDAQ:ETHZ

Flag Ship Acquisition 7/23/2025 Earnings Report

Flag Ship Acquisition logo
$15.64 -0.72 (-4.40%)
As of 04:00 PM Eastern

Flag Ship Acquisition EPS Results

Actual EPS
-$3.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Flag Ship Acquisition Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Flag Ship Acquisition Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Flag Ship Acquisition's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Flag Ship Acquisition Earnings Headlines

Notable open interest changes for October 21st
Flag Ship Acquisition (ETHZ) vs. The Competition Head to Head Survey
This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
180 Life Sciences (NASDAQ:ATNF) Trading Up 0.6% - Time to Buy?
Contrasting Flag Ship Acquisition (ETHZ) and The Competition
See More Flag Ship Acquisition Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Flag Ship Acquisition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Flag Ship Acquisition and other key companies, straight to your email.

About Flag Ship Acquisition

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

View Flag Ship Acquisition Profile

More Earnings Resources from MarketBeat